A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid- Production in Vivo

Neurodegeneration Labs, Department of Neuroscience, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
Science translational medicine (Impact Factor: 15.84). 05/2011; 3(84):84ra43. DOI: 10.1126/scitranslmed.3002254
Source: PubMed


Reducing production of amyloid-β (Aβ) peptide by direct inhibition of the enzymes that process amyloid precursor protein (APP) is a central therapeutic strategy for treating Alzheimer's disease. However, small-molecule inhibitors of the β-secretase (BACE1) and γ-secretase APP processing enzymes have shown a lack of target selectivity and poor penetrance of the blood-brain barrier (BBB). Here, we have developed a high-affinity, phage-derived human antibody that targets BACE1 (anti-BACE1) and is anti-amyloidogenic. Anti-BACE1 reduces endogenous BACE1 activity and Aβ production in human cell lines expressing APP and in cultured primary neurons. Anti-BACE1 is highly selective and does not inhibit the related enzymes BACE2 or cathepsin D. Competitive binding assays and x-ray crystallography indicate that anti-BACE1 binds noncompetitively to an exosite on BACE1 and not to the catalytic site. Systemic dosing of mice and nonhuman primates with anti-BACE1 resulted in sustained reductions in peripheral Aβ peptide concentrations. Anti-BACE1 also reduces central nervous system Aβ concentrations in mouse and monkey, consistent with a measurable uptake of antibody across the BBB. Thus, BACE1 can be targeted in a highly selective manner through passive immunization with anti-BACE1, providing a potential approach for treating Alzheimer's disease. Nevertheless, therapeutic success with anti-BACE1 will depend on improving antibody uptake into the brain.

Download full-text


Available from: Weiru Wang
  • Source
    • "An interesting concept of combining diagnostics with therapeutics, known as theranostics, for brain delivery has been extensively discussed by Ding et al. [143]. The specially designed nano-carriers are able to deliver the drugs across the BBB using various non-invasive image guided modalities [144] [145]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The blood-brain barrier (BBB) presents a combination of physical and electrostatic barriers. It is a highly complex structure that tightly regulates the movement of molecules from the blood to brain, protecting it from injuries and diseases. However, the BBB also significantly precludes the delivery of drugs to the brain, thus, preventing the therapy of a number of neurological disorders like brain cancer, epilepsy, Alzheimer’s disease, schizophrenia etc. Numerous drug delivery strategies have been developed to circumvent this barrier. Out of those, one popular approach is the use of nanoparticles. Nanoparticles form solid, colloidal drug delivery system that consists of macromolecular materials in which the active principle is dissolved, entrapped or encapsulated or onto which the active principle is adsorbed or attached. Brain targeted polymeric nanoparticles have been found to increase the therapeutic efficacy and reduce the toxicity for a large number of drugs. By coating the nanoparticles with surfactants, higher concentrations of the drugs can be delivered. The article presents various approaches used in design and delivery of nanoparticles to brain. It also reviews various patents that describe the use of nanoparticles to deliver various neurotherapeutics to brain.
    Full-text · Article · Dec 2013 · Recent Patents on CNS Drug Discovery
  • Source
    • "The residue-based decomposition analysis shows that the key residues located within the structural elements denoted as loops C and D contribute strongly to the Fab–BACE1 complex formation. These findings are in complete agreement with experimental (Atwal et al., 2011; Kornacker et al., 2007; Yu et al., 2011) and theoretical (Gutierrez et al., 2010) results aimed to locate and characterize the BACE1 exosite. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A molecular modeling study giving structural, functional, and mutagenesis insights into the anti-BACE1 Fab fragment that recognizes the BACE1 exosite is reported. Our results allow extending experimental data resulting from X-ray diffraction experiments in order to examine unknown aspects for the Fab-BACE1 recognition and its binding mode. Thus, the study performed here allows extending the inherently static nature of crystallographic structures in order to gain a deeper understanding of the structural and dynamical basis at the atomic level. The characteristics and strength of the interatomic interactions involved in the immune complex formation are exhaustively analyzed. The results might explain how the anti-BACE1 Fab fragment and other BACE1 exosite binders are capable to produce an allosteric modulation of the BACE1 activity. Our site-directed mutagenesis study indicated that the functional anti-BACE1 paratope, residues Tyr32 (H1), Trp50 (H2), Arg98 (H3), Phe101 (H3), Trp104 (H3) and Tyr94 (L3), strongly dominates the binding energetics with the BACE1 exosite. The mutational studies described in this work might accelerate the development of new BACE1 exosite binders with interesting pharmacological activity.
    Full-text · Article · Jul 2013 · Journal of biomolecular Structure & Dynamics
  • Source
    • "Aspartyl Protease β-site APP Cleavage Enzyme 1 (BACE1) is a prime therapeutic target for Alzheimer's disease. The therapeutic effect of an anti-BACE1 antibody in inhibiting Aβ production has been demonstrated in vivo [64]. To enhance the brain delivery of the anti-BACE1 antibody, a bi-specific antibody was generated by fusing a low affinity anti-TfR antibody to a high affinity anti-BACE1 antibody [65]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transport of macromolecules across the blood-brain-barrier (BBB) requires both specific and nonspecific interactions between macromolecules and proteins/receptors expressed on the luminal and/or the abluminal surfaces of the brain capillary endothelial cells. Endocytosis and transcytosis play important roles in the distribution of macromolecules. Due to the tight junction of BBB, brain delivery of traditional therapeutic proteins with large molecular weight is generally not possible. There are multiple pathways through which macromolecules can be taken up into cells through both specific and nonspecific interactions with proteins/receptors on the cell surface. This review is focused on the current knowledge of receptor-mediated endocytosis/transcytosis and brain delivery using the Angiopep-2-conjugated system and the molecular Trojan horses. In addition, the role of neonatal Fc receptor (FcRn) in regulating the efflux of Immunoglobulin G (IgG) from brain to blood, and approaches to improve the pharmacokinetics of therapeutic biologics by generating Fc fusion proteins, and increasing the pH dependent binding affinity between Fc and FcRn, are discussed.
    Full-text · Article · Jun 2013 · International Journal of Cell Biology
Show more